{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003763","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.113040+00:00","generated_at":"2026-06-06T04:04:48.589866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Integrated BioPharma Q2 revenue down 6.5% to $11.5M; net loss widens to $0.4M","bullets":["Revenue $11.5M vs $12.3M in prior-year quarter (-6.5%).","Operating loss of ~$0.5M vs ~$33K loss a year ago.","Net loss of $0.4M ($0.01 per share) vs $3K loss ($0.00) prior year.","Six-month revenue $24.4M vs $24.6M; net loss $0.4M vs $0.1M.","Two largest customers represent ~90% of total revenue; company aims to diversify by FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003763","json":"https://secwatch.observer/filing/0001437749-24-003763.json","markdown":"https://secwatch.observer/filing/0001437749-24-003763.md","text":"https://secwatch.observer/filing/0001437749-24-003763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924003763/0001437749-24-003763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924003763/inbp20240209_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:04:48.589866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dac69809e2f0ff1b093d6099a5626823c7815ca1","claim":"INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2023 results: revenue $11.5 million, net income net loss of approximately $0.4 million, EPS $0.01.","evidence_excerpt":"Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ended December 31, 2022, a decrease of $0.8 million or 6.5%. The Company had operating losses for the quarters ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924003763/0001437749-24-003763-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$11.5 million"},{"label":"Net income","value":"net loss of approximately $0.4 million"},{"label":"EPS","value":"$0.01"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}